Ardent Health Partners Files 8-K on Financials and Personnel

TL;DR

Ardent Health Partners dropped an 8-K detailing financials and leadership changes. Check it out!

AI Summary

Ardent Health Partners, Inc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition. The filing also disclosed the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements. Additionally, it included information on Regulation FD Disclosure and financial statements and exhibits.

Why It Matters

This 8-K filing provides crucial updates on Ardent Health Partners' financial performance and any significant changes in its leadership or board composition, impacting investor understanding of the company's stability and direction.

Risk Assessment

Risk Level: medium — The filing covers financial results and potential executive/director changes, which can introduce uncertainty or signal strategic shifts.

Key Players & Entities

• Ardent Health Partners, Inc. (company) — Registrant
• 0001756655 (company) — Central Index Key
• 20250113 (date) — Report Date

FAQ

Key Financial Figures

• $1,076,000 — ent, Mr. Bonick's base salary is set at $1,076,000, which base salary may be increased to
• $628,000 — , Mr. Lumsdaine's base salary is set at $628,000, which base salary may be increased to
• $200 million — ic long-term target, plus approximately $200 million of incremental revenue impact from the
• $140 million — ic long-term target, plus approximately $140 million of incremental adjusted EBITDA impact f

Filing Documents

• ardt-20250113.htm (8-K) — 58KB
• exhibit101-employmentagree.htm (EX-10.1) — 131KB
• exhibit102-employmentagree.htm (EX-10.2) — 129KB
• exhibit99-jpmpresentatio.htm (EX-99) — 35KB
• exhibit99-jpmpresentatio001.jpg (GRAPHIC) — 801KB
• exhibit99-jpmpresentatio002.jpg (GRAPHIC) — 371KB
• exhibit99-jpmpresentatio003.jpg (GRAPHIC) — 400KB
• exhibit99-jpmpresentatio004.jpg (GRAPHIC) — 440KB
• exhibit99-jpmpresentatio005.jpg (GRAPHIC) — 430KB
• 0001628280-25-001368.txt ( ) — 3911KB
• ardt-20250113.xsd (EX-101.SCH) — 2KB
• ardt-20250113_lab.xml (EX-101.LAB) — 22KB
• ardt-20250113_pre.xml (EX-101.PRE) — 13KB
• ardt-20250113_htm.xml (XML) — 3KB

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. Members of senior management of the Company are presenting at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on January 14, 2025. Materials to be discussed at the conference are included in a slide presentation available on the investor relations section of the Company's website at ir.ardenthealth.com, a copy of which is furnished as Exhibit 99 to this Form 8-K. A live webcast of the Company's presentation may also be accessed via the Company's website. On November 25, 2024, the Centers for Medicare & Medicaid Services ("CMS") approved the New Mexico state directed payment program for the period from July 1, 2024 through December 31, 2024. The approval was posted to the CMS website on December 26, 2024. The Company anticipates recording a material financial benefit in its fourth quarter 2024 financial results. However, given the timing of the approval, the Company is still finalizing the benefit and expects to disclose the amount when it reports its fourth quarter 2024 financial results. The Company's previously-disclosed 2024 financial estimates included in the Company's presentation do not reflect the impact of any benefit from the New Mexico directed payment program. As part of its presentation, management intends to offer preliminary 2025 financial commentary, which is summarized in the slide presentation posted to the investor relations section of the Company's website. The presentation summarizes key tailwinds and headwinds and captures management's view relative to 2025 analyst consensus estimates. The Company intends to provide formal 2025 guidance in February and management currently expects: Revenue growth in the mid-single digits, consistent with the Company's organic long-term target, plus approximately $200 million of incremental revenue impact from the New Mexico and Oklahoma state directed payment programs; and Adjusted EBITDA growth in the mid-single digits, which is slightly below the

Forward Looking Statements

Forward Looking Statements Certain statements contained in this item regarding future operating results or performance or business plans or prospects of the Company and any other statements not constituting historical fact are "forward-looking statements" subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Where possible, the words "anticipates," "expects," "intends," "plans," "predicts," "believes," "seeks," "estimates," "could," "would," "will," "may," "can," "continue," "potential," "should" or the negative of such terms, or other comparable expressions, as they relate to the Company or its management, have been used to identify such forward-looking statements. All forward-looking statements reflect only management's current beliefs and assumptions with respect to future business plans, prospects, decisions and results, and are based on information currently available to the Company. Accordingly, the statements are subject to significant risks, uncertainties and contingencies, which could cause the Company's actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by, these statements. Factors that could cause actual results to differ materially from current expectations, such as various factors that may affect the Company's business or financial results and which, in some instances, are beyond the Company's control, include, among others: (1) changes in government healthcare programs, including Medicare and Medicaid and supplemental payment programs and state directed payment arrangements; (2) reduction in the reimbursement rates paid by commercial payors, the Company's inability to retain and negotiate favorable contracts with private third-party payors, or an increasing volume of uninsured or underinsured patients; (3) the highly competitive nature of the healthcare industry; (4) inability to recruit and retain quality physicians, as well as increa

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: January 13, 2025 ARDENT HEALTH PARTNERS, INC. By: /s/ Stephen C. Petrovich Name: Stephen C. Petrovich Title: Executive Vice President & General Counsel

View Full Filing

View this 8-K filing on SEC EDGAR